SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 29th, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of _______ ___, 2012, between Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT brainstorM cell therapeutics inc.Brainstorm Cell Therapeutics Inc • June 29th, 2012 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the _____ year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 29th, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • New York
CONSULTING AGREEMENTConsulting Agreement • June 29th, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances)
THIS CONSULTING AGREEMENT (this “Agreement”) made as of the 31 day of May __ 2012, by and between Brainstorm Cell Therapeutics Inc., a Delaware Corporation, with offices at 605 Third Avenue, New York, NY 10158, USA (“Parent”), Brainstorm Cell Therapeutics Ltd., a wholly owned subsidiary of Parent, a private company organized under the Laws of the State of Israel, whose principal office is located at 12 Bazel Street, Petach Tiqva, Israel (the “Company”, and together with Parent, the “Group”) and Dr. Daniel Offen, Israeli I.D. No _______ residing at Kfar Haroeh 38955, Israel, Osek Mourshe” No. _______ (the “Consultant”).
